A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.

Survival rate surpasses historical outcomes in a small phase I study ...

A personalized DNA vaccine for glioblastoma, an aggressive and incurable brain cancer, appears safe and shows early signs of ...

Researchers unveil a groundbreaking DNA vaccine that supercharges immunity and boosts survival in patients with aggressive breast cancer—could this be the future of personalized cancer treatment?

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial ...

In a paper published in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic ...

In an early clinical trial, a personalized vaccine safely stimulated the immune systems of people with a fatal type of brain ...

Messenger RNA-based vaccine production has become a major industry focus, thanks to the success of jabs developed during the pandemic. However, under normal circumstances, DNA-based manufacturing may ...

The immunogenic protein associated with a recombinant DNA vaccine is made in the laboratory and injected into the vaccine recipient, while the immunogenic protein associated with a DNA vaccine is ...